Prevention of cyclophosphamide-induced ovarian damage by concomitant administration of GnRHa in mice: A dose-dependent relationship?

Basit Öğe Kaydı
dc.authorscopusid7003740112
dc.authorscopusid6504449254
dc.authorscopusid7004415692
dc.authorscopusid6603302570
dc.authorscopusid7004147676
dc.authorscopusid6701899425
dc.authorscopusid6602721312
dc.contributor.authorYüce M.A.
dc.contributor.authorBalkani Kaplan P.
dc.contributor.authorGücer F.
dc.contributor.authorDo?anay L.
dc.contributor.authorAltaner S.
dc.contributor.authorCanda T.
dc.contributor.authorYardim T.
dc.date.accessioned2024-06-12T10:28:08Z
dc.date.available2024-06-12T10:28:08Z
dc.date.issued2004
dc.description.abstractObjective (s): This experimental study investigates the dose-related effects of cyclophosphamide (Cy) on primordial follicular reserve in young mice, and examines whether the concomitant administration of a gonadotropin-releasing hormone agonist (GnRHa) may protect gonadal reserve, even at different doses of Cy. Methods: Forty sexually mature virginal Balb/c mice aged five to six weeks were administered different doses (0, 50, 75,100 mg/kg) of Cy. Another 40 animals were treated with increasing doses (0, 50, 75, 100 mg/kg) of Cy in combination with GnRHa. GnRHa treatment was initiated one week prior to chemotherapy and also continued after chemotherapy for one week. The ovaries were removed seven days after Cy administration and the total number of primordial follicles in both ovaries was counted. Results: Primordial follicular destruction occurred at all levels of Cy exposure. There was a positive correlation between increasing doses of Cy and higher proportion of follicular loss (p < 0.0001). GnRHa was not able to protect against the chemotherapy-induced negative effect on primordial follicular count at low doses (50 mg/kg and 75 mg/kg). Mean ± SD primordial follicle count in the 100 mg/kg Cy-treated group was significantly lower than in the 100 mg/kg Cy + GnRHa treatment group (73.9 ± 33.1 vs 89 ± 17.9, p = 0.047). Conclusion: Our data suggest a possible ovarian protective effect of GnRHa cotreatment only at high doses of Cy treatment. However, in spite of co-administration of GnRHa, loss of primordial follicular reserve occurred at all doses of Cy in mice.en_US
dc.identifier.endpage631en_US
dc.identifier.issn0392-2936
dc.identifier.issue5en_US
dc.identifier.pmid15493183en_US
dc.identifier.scopus2-s2.0-4644317291en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage628en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17090
dc.identifier.volume25en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofEuropean Journal of Gynaecological Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChemotherapy; Cyclophosphamide; Gnrha; Ovarian Toxicity; Premature Ovarian Failure; Primordial Follicles; Primordial Follicular Reserveen_US
dc.subjectCyclophosphamide; Gonadorelin Agonist; Leuprorelin; Animal Experiment; Animal Model; Animal Tissue; Article; Cell Count; Controlled Study; Correlation Analysis; Dose Response; Drug Effect; Drug Efficacy; Drug Exposure; Female; Mouse; Mouse Strain; Nonhuman; Organ Injury; Ovary Disease; Ovary Follicle; Premature Ovarian Failure; Protection; Animals; Antineoplastic Agents, Alkylating; Cyclophosphamide; Female; Gonadotropin-Releasing Hormone; Injections, Intraperitoneal; Mice; Mice, Inbred Balb C; Ovarian Diseases; Ovarian Follicle; Protective Agentsen_US
dc.titlePrevention of cyclophosphamide-induced ovarian damage by concomitant administration of GnRHa in mice: A dose-dependent relationship?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu